Results 251 to 260 of about 8,468,954 (280)

Drug–Drug–Gene Interactions in Cardiovascular Medicine [PDF]

Pharmacogenomics and Personalized Medicine, 2022
Cardiovascular disease remains a leading cause of both morbidity and mortality worldwide. It is widely accepted that both concomitant medications (drug-drug interactions, DDIs) and genomic factors (drug-gene interactions, DGIs) can influence cardiovascular drug-related efficacy and safety outcomes. Although thousands of DDI and DGI (aka pharmacogenomic)
Innocent G Asiimwe, Munir Pirmohamed
exaly   +5 more sources

Some of the next articles are maybe not open access.

Related searches:

Drug–drug–gene interaction risk among opioid users in the U.S. Department of Veterans Affairs

Pain, 2022
Abstract Response to analgesic therapy is influenced by several factors including genetics and drug–drug interactions. Pharmacogenetic (PGx) variants in the CYP2D6 gene modify response to opioids by altering drug metabolism. We sought to determine the potential impact of PGx testing on the care of Veterans with noncancer pain prescribed ...
Catherine Chanfreau-Coffinier, Sony Tuteja, Leland E. Hull, Sally MacDonald, Olga Efimova, Jill Bates, Deepak Voora, David W. Oslin, Scott L. DuVall, Julie A. Lynch   +9 more
openaire   +2 more sources

Insights Into Pharmacogenetics, Drug-Gene Interactions, and Drug-Drug-Gene Interactions

Drug Metabolism Reviews
This review explores genetic contributors to drug interactions, known as drug-gene and drug-drug-gene interactions (DGI and DDGI, respectively). This article is part of a mini-review issue led by the International Society for the Study of Xenobiotics (ISSX) New Investigators Group.
Benjamin J Maldonato, Laura E Russell, Jaydeep Yadav   +2 more
exaly   +3 more sources

Severe hyperglycaemia following pazopanib treatment: The role of drug‐drug‐gene interactions in a patient with metastatic renal cell carcinoma—A case report

Journal of Clinical Pharmacy and Therapeutics, 2020
Pazopanib is a tyrosine kinase inhibitor with hyperglycaemia as a known adverse event, but case reports of severe hyperglycaemia are exceptional. We report a case of severe hyperglycaemia following pazopanib administration in a patient with metastatic renal cell carcinoma.Severe hyperglycaemia developed in a patient one month following initiation of ...
Darija Kuruc Poje, Nada Božina, Livija Šimičević, Igor Žabić   +3 more
openaire   +4 more sources

PM-TOM: A Method for Finding Personalized Polypharmacy Therapies with Minimal Adverse Drug-Drug, Drug-Gene and Drug-Condition Interactions

2020
Polypharmacy therapies, quite frequent in older populations, pose significant health risks for patients due to a high possibility of their cumulative adverse drug reactions. We present Personalized Medicine Therapy Optimization Method (PM-TOM) for the discovery of polypharmacy therapies with minimal drug-drug interactions, drug-gene interactions, and ...
Adnan Kulenovic, Azra Lagumdzija-Kulenovic   +1 more
openaire   +2 more sources

Model Informed Drug Development and Precision Dosing for Drug-Drug-Gene-Interactions: Application of Physiologically-Based Pharmacokinetic Modeling

2021
Der globale Arzneimittelbedarf steigt kontinuierlich an. Infolgedessen kommt es vermehrt zu unerwünschten Arzneimittelwirkungen, die eine Gefahr für Patienten darstellen. Eine wichtige Rolle beim Auftreten unerwünschter Arzneimittelwirkungen spielen Arzneimittel-Arzneimittel- und Arzneimittel-Gen-Wechselwirkungen. Um das Risiko solcher Wechselwirkungen
openaire   +1 more source

Rhabdomyolysis in kidney transplant patient with COVID-19: possible role of remdesivir and atorvastatin drug-drug-gene interactions

2022
Introduction Because of very variable clinical presentation of Covid-19 and polypharmacy in elderly, sometimes is difficult to distinguish between the drug-drug, disease- drug or drug-drug-gene induced side effects. Description A 63 –year old Caucasian woman with kidney transplant, was hospitalized due to Covid-19 infection.
Božina, Nada, Šimičević, Livija, Osmanović, Jelena, Ganoci, Lana   +3 more
openaire  

Opioid-Related Genetic Polymorphisms of Cytochrome P450 Enzymes after Total Joint Arthroplasty: A Focus on Drug-Drug-Gene Interaction with Commonly Coprescribed Medications.

The Orthopedic clinics of North America, 2022
Pharmacogenomic testing, together with the early detection of drug-drug-gene interactions (DDGI) before initiating opioids, can improve the selection of dosage and reduce the risk of adverse drug interactions and therapeutic failures following Total Joint Arthroplasty. The variants of CYP genes can mediate DDGI.
Brendan J, Farley, Mohamed E, Awad, Paige, Anderson, Ali S, Esseili, Justin, Hruska, Gamal, Mostafa, Khaled J, Saleh   +6 more
openaire   +1 more source

Severe CNS depression with duloxetine, ciprofloxacin and CYP2D6 deficiency—role and recognition of drug-drug-gene interactions

European Journal of Clinical Pharmacology, 2022
Matthias Hoffmann, Stefan Russmann, David F. Niedrig   +2 more
openaire   +2 more sources

INSPIRATION - Qualified open systems pharmacology modeling network of drug-drug-gene-interactions

[no abstract available]
openaire   +1 more source